All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02
Podocyte foot process effacement is a hallmark of Alport syndrome
Together with previously announced rapid and sustained proteinuria remission in one patient in Phase 2 clinical study, these biopsy results strongly support decision to advance ELX-02 into a pivotal trial in Alport syndrome
https://finance.yahoo.com/news/eloxx-pharmaceuticals-reports-drug-response-120000129.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.